Hehlmann R
III. Medizinische Klinik, Klinikum Mannheim, Universität Heidelberg.
Schweiz Med Wochenschr. 1994 Jan 11;124(1-2):37-43.
New developments in relation to chronic myelogenous leukemia (CML) are characterized by progress in knowledge of pathogenesis, diagnostic improvement such as nosology of Philadelphia-negative CML and diagnosis of minimal residual disease by molecular techniques, advances in drug therapy with hydroxyurea or interferon alpha, and progress in bone marrow transplantation through availability of unrelated donors. In addition, the recognition of suitable prognostic parameters indicates that risk adapted therapy may become possible.
慢性粒细胞白血病（CML）的新进展体现在发病机制认识的进步、诊断的改进（如费城阴性CML的分类学及通过分子技术诊断微小残留病）、羟基脲或α干扰素药物治疗的进展以及通过无关供体骨髓移植的进步。此外，对合适预后参数的认识表明风险适应性治疗可能成为现实。
